Credit Suisse analyst Katie Tryhane maintains Fulgent Genetics (NASDAQ:FLGT) with a Underperform and raises the price target from $55 to $65.
Gannett Q3 GAAP EPS $(0.39) Versus $0.09 Prior Year, Sales $717.90M Miss $745.50M Estimate
Gannett (NYSE:GCI) reported quarterly losses of $(0.39) per share versus $0.09 in the same period last year. The company reported quarterly sales of $717.90 million which missed the analyst consensus estimate of $745.50